Antares Pharma to Report Third Quarter 2020 Financial and Operating Results
October 22 2020 - 8:30AM
Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a
pharmaceutical technology company, today announced it will release
its third quarter 2020 financial and operating results on Thursday,
November 5, 2020, before the market opens.
Antares will host a conference call
on Thursday, November 5, 2020 at 8:30am ET to
discuss the results. The dial-in numbers are (888) 204-4368 for
domestic callers and (323) 994-2093 for international callers. The
conference ID number is 6925216. A live webcast and replay of the
conference call will be available online from the investor
relations section of the Antares Pharma corporate website
at www.antarespharma.com.
About Antares Pharma
Antares Pharma, Inc. is a pharmaceutical
technology company focused primarily on the development and
commercialization of self-administered injectable pharmaceutical
products using advanced drug delivery auto injector technology. The
Company has a portfolio of proprietary and partnered commercial
products with several product candidates in various stages of
development, as well as significant strategic alliances with
industry leading pharmaceutical companies including Teva
Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc.
(AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd.
(Idorsia). Antares Pharma’s FDA-approved products include XYOSTED®
(testosterone enanthate) injection, OTREXUP® (methotrexate)
injection for subcutaneous use and Sumatriptan Injection USP, which
is distributed by Teva. The Company also markets NOCDURNA®
(desmopressin acetate) in the U.S., which was licensed from Ferring
Pharmaceuticals.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe
harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are subject to certain risks and uncertainties that can
cause actual results to differ materially from those described.
Factors that may cause such differences include, but are not
limited to: the Company’s ability to achieve the reinstated 2020
full-year revenue guidance; the uncertainty
regarding the duration, scope and severity of the COVID-19 pandemic
and the mitigation measures and other restrictions implemented in
response to the same and the impact on
demand for our products, new patients and
prescriptions, future revenue, product supply, and
our overall business, operating results and financial
condition; successful commercialization of
NOCDURNA® in the United States
and market acceptance and future revenue from the
same: adequate reimbursement
coverage and commercial success of
XYOSTED® and future
revenue from the same; market acceptance of Teva’s
generic epinephrine auto-injector product and future revenue from
the same; our expectations regarding whether the
FDA will be successful in
pursuing withdrawal of
approval for AMAG’s Makena®
subcutaneous auto injector following the recent FDA
advisory committee meeting and future
prescriptions, market acceptance and revenue from
the same ; Teva’s ability to successfully
commercialize VIBEX® Sumatriptan
Injection USP and the amount of revenue from the same; continued
growth of prescriptions and sales of
OTREXUP®;
successful development including the timing and results of
the clinical bridging and Phase 3 clinical trial of the
drug device combination product for
Selatogrel with Idorsia Pharmaceuticals
and FDA and global regulatory approvals and future revenue from the
same; FDA approval of Teva’s pending ANDA for generic
Forteo and future revenue from the
same; the timing and results of the Company’s or
its partners’ research projects or clinical trials of product
candidates in development; actions by the FDA or other regulatory
agencies with respect to the Company’s products or product
candidates of its partners; continued growth in product,
development, licensing and royalty revenue; the Company’s ability
to meet loan extension and interest only payment milestones and the
ability to repay the debt obligation to Hercules Capital; the
Company’s ability to obtain financial and other resources for its
research, development, clinical, and commercial activities and
other statements regarding matters that are not historical facts,
and involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as ''may'', ''will'', ''should'',
''would'', ''expect'', ''intend'', ''plan'', ''anticipate'',
''believe'', ''estimate'', ''predict'', ''potential'', ''seem'',
''seek'', ''future'', ''continue'', or ''appear'' or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K, and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in
this press release. All forward-looking statements are based on
information currently available to the Company on the date hereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by
law.
Contact:Tram
BuiVice President, Corporate Communications and Investor
Relations609-359-3016tbui@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Apr 2023 to Apr 2024